We initiate coverage of Canatu, a leading player in advanced carbon nanotubes (CNTs), with a Buy rating and a EUR15 price target. Recently listed post-combination with Lifeline SPAC 1 in September 2024, Canatu offers a compelling growth opportunity, well-positioned to capitalise on the commercialis
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.